Barinthus Biotherapeutics PLBRNS
13F holders, Q4 2024 (December 31)At the end of Q4 2024, 16 institutions reported holding Barinthus Biotherapeutics PL (BRNS) in their 13F filings, down 3 from Q3 2024. 0 opened new positions and 4 sold out. The largest holders were M&G PLC ($5.2M), Alphabet Inc. ($1.8M) and HSG Holding Ltd ($1.4M). 2 famous investors held it, including Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio) and Israel Englander (0.0% of Millennium Management's portfolio).
- Company
- Barinthus Biotherapeutics PL
- CUSIP
- 91864C107
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 4 | $689K |
All 13F filers, Q3 2024 → Q4 2024: 8,012 shares bought and 597,565 shares sold, net −589,553 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 16 holders
| M&G PLC | 0.03% | No change | 5,197,349 | $5.2M |
| Alphabet Inc. | 0.11% | No change | 1,513,644 | $1.8M |
| HSG Holding Ltd | 0.06% | No change | 1,420,473 | $1.4M |
| DC Funds, LP | 21.77% | No change | 642,204 | $776K |
| Gilead Sciences, Inc. | 0.05% | — | 620,351 | $749K |
| Johns Hopkins University | 0.01% | No change | 122,237 | $148K |
| Baird Financial Group, Inc. | 0.00% | No change | 92,461 | $112K |
| Renaissance Technologies | 0.00% | Add +25.8% | 35,100 | $42K |
| Ipswich Investment Management Co., Inc. | 0.01% | Reduce -22.1% | 17,575 | $21K |
| Janney Montgomery Scott LLC | 0.00% | No change | 15,008 | $18K |
| Geode Capital Management, LLC | 0.00% | No change | 11,568 | $14K |
| Millennium Management | 0.00% | Add +8.0% | 10,960 | $13K |
| Catalina Capital Group, LLC | 0.00% | Reduce -50.2% | 10,216 | $12K |
| Morgan Stanley | 0.00% | Reduce -33.1% | 8,021 | $10K |
| New England Capital Financial Advisors LLC | 0.00% | No change | 104 | $126 |
| Rhumbline Advisers | 0.00% | No change | 60 | $72 |
"% of holder's portfolio" is BRNS's weight in each manager's 13F, not the share of Barinthus Biotherapeutics PL the manager owns.